dr. gold on the future of osimertinib in lung cancer
Published 6 years ago • 1.5K plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:52
dr. goldberg discusses osimertinib in nsclc
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc
-
1:00
dr. husain on the future of monitoring t790m in lung cancer
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
5:45
osimertinib in t790m-mutant lung cancer
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
1:06
dr. shum on patient consultation of osimertinib in nsclc
-
0:48
dr. govindan on the future of egfr-mutant nsclc
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
10:20
role of adjuvant osimertinib in early stage nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:26
dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
-
6:06
osimertinib, the standard for egfr nsclc